Jeremy Grantham's LRMR Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 13,065 shares of Larimar Therapeutics, Inc. (LRMR) worth $58,793, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Jeremy Grantham has initiated a new position in LRMR, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Larimar Therapeutics (LRMR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Larimar Therapeutics (LRMR) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +13,065 | New Buy | 13,065 | $4.50 |
Jeremy Grantham's Larimar Therapeutics Investment FAQs
Jeremy Grantham first purchased Larimar Therapeutics, Inc. (LRMR) in Q1 2026, acquiring 13,065 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Larimar Therapeutics, Inc. (LRMR) for 1 quarters since Q1 2026.
Jeremy Grantham's largest addition to Larimar Therapeutics, Inc. (LRMR) was in Q1 2026, adding 13,065 shares worth $58,793.
According to the latest 13F filing for Q1 2026, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 13,065 shares of Larimar Therapeutics, Inc. (LRMR), valued at approximately $58,793.
As of the Q1 2026 filing, Larimar Therapeutics, Inc. (LRMR) represents approximately 0.00% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Larimar Therapeutics, Inc. (LRMR) was 13,065 shares, as reported at the end of Q1 2026.